Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

ckd > mineral bone disease > Flashcards

mineral bone disease Flashcards

(58 cards)

Start Studying
1
Q

What are the mechanisms that potentiate hyperparathyroidism in CKD?

A
  1. Phosphate retention
  2. Hypocalcemia
  3. Decreased production of 1,25-dihydroxyvitaminD3 -> also leads to hypocalcemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Monitoring parameters for CKD-MBD

A

Calcium and Phosphorous, iPTH, and 25-OH Vitamin D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Corrected calcium equation

A

measured calcium + 0.8(4 - albumin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

CKD Stage 3 Monitoring Parameters

A

Calcium and Phos: Q6-12 months
iPTH: Q12 months
25-OH Vitamin D: at baseline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CKD Stage 4 Monitoring Parameters

A

Calcium and Phos: Q3-6 months
iPTH: Q3-12 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

CKD Stage 5 Monitoring Parameters

A

Calcium and Phos: Q1-3 months
iPTH: Q3-6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are some consequences of CKD-MBD?

A
  1. CV Disease
  2. Bone Disease
  3. Calciphylaxis (CUA)

CUA = calcific uremic arteriolopathy ~ extravascular calcification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

types of renal osteodystrophy (2)

A
  1. adynamic bone osteomalacia
  2. ostetis fibrosa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

adynamic bone osteomalacia vs. ostetis fibrosa

A

adynamic bone osteomalacia = over-treated hyperparathyroidism -> low bone turnover

ostetis fibrosa = under-treated hyperparathyroidism -> high bone turnover

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

goals of treatment of CKD-MBD (4)

A
  1. prevent consequences of cardiovascular and extravascular calcification
  2. prevent the development of secondary hyperparathyroidism and renal osteodystrophy
  3. maintain critical biochemical parameters (Ca, Phos, and iPTH) within target ranges
  4. Prevent mortality (NONE decrease mortality)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

General Approach to Pharmacologic Treatment of CKD-MBD

A

First line: Phosphate binders
Second line: Activated Vitamin D (or calcimimetic)
Third line: Calcimimetic (or activated vitamin D - whichever one you didn’t choose for 2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

how do phosphate binders help treat CKD-MBD?

A

they help prevent the initial pathologic mechanism of phosphate retention by binding phosphate in the diet and preventing absorption!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Phosphate Pyramid

A

Dark sodas (lots of phosphate)
Egg white, fruits and veggies, protein-free products (less phosphate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

If corrected calcium is LOW, what phosphate binder do you use…?

A

Calcium based binder:
Less Ca2+ More $ = Calcium acetate (PhosLo)

More Ca2+ Less $ = Calcium carbonate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Calcium based binder effects

A

increases serum Ca2+ and decreases serum phosphate concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Calcium acetate

A

Calcium based phosphate binder
PhosLo
25% elemental Ca2+
Less Ca2+ and More $
Rx only
2x phosphate binding capacity vs. carbonate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Calcium carbonate

A

Calcium based phosphate binder
40% elemental Ca2+
-> MORE risk of hypercalcemia
More Ca2+ and Less $
OTC
*requires acidic pH for phosphate binding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

If corrected calcium is NORMAL-HIGH, what phosphate binder do you use…?

A

Non-Calcium based binder
First line: Sevelamer
Lanthanum carbonate (chewable)
Ferric citrate (iron deficiency anemia)
Sucroferric oxyhydroxide (lowers pill burden)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Sevelamer dosing

A

based on serum phospahte (higher = more drug)
5.5-7.5 mg/dL: 800 mg PO TID
7.5-9 mg/dL: 1200-1600 mg PO TID
> 9 mg/dL: 1600 mg PO TID

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Sevelamer

A

Non-calcium based phosphate binder
Renvela
1st line!

also helps to decrease LDL and increase HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Sevelamer DDIs

A

take other meds 1 hour before or 3 hours after taking sevelamer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

adverse effects of Sevelamer

A

Gi upset, DIARRHEA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Lanthanum carbonate

A

Non-calcium based phosphate binder
Fosrenol
Chewable!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

counseling point for Lanthanum carbonate

Study These Flashcards
A

tablet MUST be chewed

25
adverse effects of Lanthanum carbonate
GI upset, lanthanum accumulation
26
Lanthanum carbonate DDIs
take other meds 1 hour before and 3 hours after taking Lanthanum carbonate (not as many DDIs as Sevelamer)
27
Ferric citrate
Non-calcium based phosphate binder Auryxia IDA -> iron supplement AND phosphate binder
28
dosing of Ferric citrate
420 mg ferric iron 92 tabs) PO TID
29
adverse effects of Ferric citrate
GI, diarrhea, iron overload, stool discoloration
30
Sucroferric oxyhydroxide
Non-calcium based phosphate binder Velphoro lowers pill burden VERY potent phosphate binder and ALSO CHEWABLE
31
dosing of sucroferric oxyhydroxide
500 mg iron PO TID MUST be chewed
32
adverse effects of sucroferric oxyhydroxide
GI upset, diarrhea
33
what is an advantage of sucroferric oxyhydroxide?
lower pill burden (non-inferior to sevelamer carbonate)
34
if corrected serum calcium AFTER phosphate binding is at a stable dose is NORMAL-LOW...
activated vitamin D and analogs endogenous: calcitriol (rocaltrol) less increase in Ca/PO4: paricalcitol doxercalciferol (hectorol) (less hypercalcemia and hyperphosphatemia)
35
if corrected serum calcium AFTER phosphate binding is at a stable dose is NORMAL-HIGH...
Calcimimetic (dec. serum Ca) PO: cinacalcet (sensipar) IV: etelcalcitide (parsabiv)
36
KDIGO 2017 Guidelines for serum calcium, serum phosphate, and iPTH
goal serum calcium: avoid hypercalcemia; asymptomatic hypocalcemia is ok goal serum phosphate: towards the normal range (3.5-5.5 mg/dL) goal iPTH: 2-9x ULN (~ 150-600 pg/mL)
37
Phosphorous Balance and Hemodialysis
to achieve neutral phosphate balance, binders must remove 257 mg/day
38
most important counseling point for phospahte binders?
TAKE WITH FOOD!
39
what are some adverse effects of calcium based phosphate binders?
- abdominal discomfort, nephrolithiasis - "Stones, Bones, and Abdominal Groans" - Calciphylaxis - systemic calcification
40
Calcium Based Phosphate Binders DDIs
Fluroquinolones Levothyroxine (Synthroid) Iron separate administration ~ 2 hours
41
Non-Calcium Based Phosphate Binders
First line: Sevelamer carbonate *HCl not used due to worsening metabolic acidosis Second line: Lanthanum carbonate (Fosrenol) Third line: Aluminum hydroxide (Amphojel)
42
what is a disadvantage of Sevelamer and Lanthanum carbonate?
they are both expensive!
43
Aluminum based binders
LAST LINE aluminum hydroxide (amphojel) very effective phosphate binding
44
adverse effects of aluminum hydroxide
GI upset, CNS toxicity (dialysis encephalopathy), microcytic anemia risk of aluminuk toxicity -> inc. serum aluminum leads to aluminum deposition and toxicity (osteomalacia, microcytic anemia, neurologic sequelae) also ESA resistance
45
Goals of therapy for Phosphate Binders
Corrected calcium: 8.5-10.2 mg/dL (avoid hypercalcemia; asymptomatic hypocalcemia is ok) Normal serum phosphorous towards the normal range: 2.7-4.6 mg/dL (or 3.5-5.5 for some)
46
Clinical Pearls for Phosphate Binders
- adherence is critical - counsel to TAKE WITH FOOD - combo of calcium AND non-calcium binders can be used
47
when should vitamin D/calcitriol be used in a CKD-MBD patient?
1. elevated iPTH despite calcium and phosphate at goal 2. persistent hypocalcemia with hyperparathyroidism
48
when should vitamin D/calcitriol NOT be used in a CKD-MBD patient?
hypercalcemia and/or hyperphosphatemia (use calcimimetics and optimize phosphate binders first!!!)
49
what is the target therapy with vitamin D/calcitriol agents in ESRD?
iPTH maintained 2-9x ULN (~150-600 pg/mL) prevent hypercalcemia
50
what is recommended in CKD and ESRD if vitamin D deficiency?
serum 25-hydroxycholecalciferol < 30 ng/mL ergocalciferol (vitamin D2) cholecalciferol (vitamin D3) *inactive forms of Vitamin D*
51
ergocalciferol and cholecalciferol
vitamin D2 and D3 - poor conversion to active form (calciferol) in ESRD - available OTC - inexpensive
52
calcifediol (rayaldee)
prohormone of active form of vitamin D approved for CKD stages 3 and 4 (NOT ESKD; no dialysis or CKD 5)
53
initiation requirements for calcifediol
serum calcium must be < 9.8 mg/mL and phosphorous
54
side effects of calcifediol
hypercalcemia and hyperphosphatemia
55
cinacalcet MOA
calcimimetic -> sensitizes parathyroid gland
56
adverse effects of cinacalcet
GI - N/V very common hypocalcemia - paresthesias, myalgia, cramping, tetany monitor Ca for 1 week then monthly QT prolongation (due to hypocalcemia)
57
etelcalcetide (parsabiv)
IV calcimimetic dosed at HD less GI side effects hypocalcemia QT prolongation
58
General Treatment Algorithm
Treat to targets of: - towards normal phosphate range - avoiding hypercalcemia; asymptomatic hypocalcemia is ok **USE CORRECTED CALCIUM!!** - iPTH ~ 150-600 pg/mL Start with Phosphate Binders - initial choice based on serum calcium (CORRECTED) Add active Vitamin D or calcimimetic based on trends of Ca, Phos, and iPTH - active vitamin D if Ca LOW, Phos at target, iPTH HIGH - calcimimetic if Ca HIGH, Phos at target, iPTH HIGH

ckd (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions